2024年5月17日 – 云顶国际与GV Safety Assessment Platform（GVSAP）签署战略合作协议。GVSAP是GV Research Platform（GVRP）的子公司，总部位于印度海得拉巴医药城（Genome Valley），具有领先的综合研发平台，可提供全面的临床前研究解决方案。该合作的达成将为印度生物医药研发人员带来云顶国际子品牌BioMice百奥动物的人源化小鼠等货架型模型以及基因编辑服务。详情可阅读下方新闻：

来源：https://www.businesswireindia.com/gv-safety-assessment-platform-gvsap-and-biocytogen-forge-strategic-collaboration-to-accelerate-biopharmaceutical-innovation-90079.html

Hyderabad, Telangana, India – May 17, 2024 – GV Safety Assessment Platform (GVSAP), a leading integrated R&D enabler offering comprehensive preclinical research solutions, proudly announces a groundbreaking partnership with Biocytogen, a leader in industry-leading technologies that propel drug discovery. This collaboration marks a significant advancement in biomedical research, aimed at bolstering the R&D endeavors of Indian researchers by democratizing cutting-edge tools and technologies.

Through this strategic alliance, Indian biomedical researchers will gain unparalleled access to Biocytogen's expertise in providing Humanized research models, other Off-the-shelf models and products, and Gene Targeting Services offered under Biocytogen’s sub-brand BioMice.

Headquartered at Genome Valley, Hyderabad, GVSAP, a subsidiary of GV Research Platform (GVRP), boasts AAALAC International and OECD-GLP compliant facilities spanning over 30,000 square feet. With a state-of-the-art modern vivarium featuring dedicated SPF breeding and preclinical testing areas, GVSAP ensures the highest standards of research integrity and animal welfare.

Kalyan Korisapati, Co-Founder & CEO of GVRP, expressed his enthusiasm, stating, “Our company, GVSAP already serves as a preferred distributor of high-quality traditional and immunocompromised SPF rodents for customers in India. Our collaboration with Biocytogen marks a monumental milestone in our mission to propel biomedical innovation forward. Biocytogen’s expertise in creating engineered models that mimic the interaction between drug and human targets aims to provide the Indian Biopharma community with convenient access to precision research.”

Yuelei Shen, CEO of Biocytogen, emphasized the partnership's potential, stating, “Biocytogen empowers researchers with innovative tools and technologies. With India's rising prominence in biopharma R&D, it's a pivotal hub for advanced solutions like humanized mice. By leveraging GVSAP’s extensive reach in the Indian biopharma community, we are poised to catalyze pioneering discoveries and accelerate Indian biomedical research through this collaboration.”

By amalgamating GVSAP's global network, top-tier infrastructure, and skilled talent pool with Biocytogen's unparalleled expertise in genetic engineering and model development, the alliance aims to expedite the innovation of scientific discoveries.

For media inquiries and further information, please contact:
info@gvrp.in or visit www.gvrp.in and https://en.czck88.com/